March/April 2013

A Rose by Any Other Name: Imperatives for Biosimilar Naming

April 09, 2013

The American Journal of Pharmacy Benefits

With the approval of biosimilars in the United States, a key safety issue is the naming configuration. This article discusses the issues and options around biosimilar naming.

"Here Us Now:" The Patient Community Has Spoken

April 09, 2013

The American Journal of Pharmacy Benefits

A new documentary has been released that underscores the need for accelerating alternative pathways for new discoveries that hold the promise for curing patients.

Trends in Statin Treatment Costs and Potential Impact of Novel Therapies

April 08, 2013

The American Journal of Pharmacy Benefits

Generic atorvastatin led to an increase in generic dispensing rate and a reduction in the cost of treatment for patients requiring cholesterol-lowering treatment. The upcoming introduction of the PCSK9 inhibitor may change this trend.

Hormone Therapy Adherence and Costs in Women With Breast Cancer

April 08, 2013

The American Journal of Pharmacy Benefits

Suboptimal adherence to hormone therapy was associated with higher medical costs, but optimal adherence was not associated with total cost savings across a 4-year period.